24 results
Thumbnail

D3.100 - Assessment of the impact of psychotropic drugs, antihistamines, and corticosteroids on the interpretation of skin tests in allergology

Thumbnail

D3.101 - Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates

Thumbnail

D3.93 - Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan

Thumbnail

D3.106 - Real-life outcomes of rapid drug desensitization to taxanes

Thumbnail

D3.94 - Good Practice Recommendations for Basophil Activation Test (BAT) Data Analysis in Routine and High-Background Settings

Thumbnail

D3.95 - Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances

Thumbnail

D3.96 - High burden of latent aeroallergen sensitization in healthy urban medical students: a blinded skin prick test study from South India

Thumbnail

D3.97 - Allergic contact dermatitis confirmed by repeated open application test in a 68‑year‑old patient

Thumbnail

D3.98 - An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology

Thumbnail

D3.104 - Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform

Thumbnail

D3.105 - Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy

Thumbnail

D3.107 - Comparison of Cupressaceae sensitization allergens in a large Spanish cohort

Thumbnail

D3.103 - Comprehensive Allergen Characterization for Standardized Basophil Activation Testing

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis